CAR-T Cells Targeting IL-1RAP Produced in a Closed Semi-Automatic System Are Ready for the First Phase I Clinical Investigation in Humans

Researchers developed a new medical drug candidate for acute myeloid leukemia, a CAR targeting interleukin-1 receptor accessory protein (IL-1RAP) expressed by leukemia stem cells.